Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00411645 · ClinicalTrials.gov registry record · Phase 3
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
A Phase 3 study of Cytomegalovirus Infections, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 681
- Enrollment target
- 20
- Study locations
NCT00411645 is a Phase 3 study of Cytomegalovirus Infections that has completed, run by Shire. The registered enrollment target is 681 participants, above the 174-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (291% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00411645, a Phase 3 study of Cytomegalovirus Infections, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 681 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
Conditions Studied
Interventions
- OTHER placebo
- DRUG maribavir
Study Locations (20)
California
- City of Hope Medical Center - Duarte
- Scripps Green Hospital - La Jolla
- UCSD Moores Center - La Jolla
- UCLA Medical Center - Los Angeles
- University of California, San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Illinois
- Northwestern University Medical Center - Chicago
- University of Chicago - Chicago
- Loyola University - Maywood
Florida
- Shands Hospital - Gainesville
- H. Lee Moffitt Cancer Center - Tampa
Kentucky
- University of Kentucky Chandler Medical Center - Lexington
- University Medical Center University of Louisville Hospital - Louisville
Arkansas
- University of Arkansas Myeloma Institute - Little Rock
Colorado
- Rocky Mountain Cancer Center - Denver
Georgia
- Emory University - Atlanta
Indiana
- St Francis Hospital - Beech Grove
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 681 participants |
| Start Date | 2006-12-13 |
| Est. Completion | 2009-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00411645
The ClinicalTrials.gov registry entry for NCT00411645 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 681 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 24 other Cytomegalovirus Infections trials with a reported enrollment target (291% higher). The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cytomegalovirus Infections appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00411645 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT00411645 about?
NCT00411645 is a clinical study titled "Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients". The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
What is the current status of trial NCT00411645?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 681 participants. The study started on 2006-12-13. Estimated completion is 2009-05-23.
What conditions does trial NCT00411645 study?
This clinical trial studies the following conditions: Cytomegalovirus Infections.
What interventions are being tested in trial NCT00411645?
The interventions under investigation include: placebo (OTHER), maribavir (DRUG).
Who is sponsoring clinical trial NCT00411645?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00411645 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
RECRUITING · Phase 3
-
A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients
COMPLETED · Phase 3
-
A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.
COMPLETED · Phase 3
-
The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
COMPLETED · Phase 3
-
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
RECRUITING · Phase 4
-
Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.